Actively Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Led by Alkermes, Inc. · Updated on 2026-05-06
176
Participants Needed
8
Research Sites
60 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.
CONDITIONS
Official Title
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing and able to understand and follow study requirements, including lifestyle, contraception, actigraphy, and diary adherence
- If treated for obstructive sleep apnea (OSA), adherence to primary OSA therapy for 30 days before and during the study
- Meets diagnostic criteria for Narcolepsy Type 2 according to ICSD-3-TR, confirmed by PSG/MSLT evaluations
You will not qualify if you...
- Has other sleep disorders or conditions affecting the sleep-wake cycle
- Has other significant illnesses, diseases, abnormalities, or surgeries that may affect safety or study participation
- Currently enrolled in another interventional clinical trial or used investigational drugs/devices within 30 days prior to study start
- Previously participated in Study ALKS 2680-202
- Pregnant, breastfeeding, or planning pregnancy during the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 8 locations
1
Alkermes Investigational Site
Brandon, Florida, United States, 33511
Actively Recruiting
2
Alkermes Investigational Site
Macon, Georgia, United States, 31210
Actively Recruiting
3
Alkermes Investigational Site
Lansing, Michigan, United States, 48911
Not Yet Recruiting
4
Alkermes Investigational Site
Cincinnati, Ohio, United States, 45245
Actively Recruiting
5
Alkermes Investigational Site
Wyomissing, Pennsylvania, United States, 19610
Actively Recruiting
6
Alkermes Investigational Site
Columbia, South Carolina, United States, 29201
Actively Recruiting
7
Alkermes Investigational Site
Austin, Texas, United States, 78731
Actively Recruiting
8
Alkermes Investigational Site
Sugar Land, Texas, United States, 77478
Actively Recruiting
Research Team
D
Director Clinical Trial Manager
CONTACT
D
Director Clinical Trial Manager
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here